BCP
PDLI

Berkeley Capital Partners’s PDL BioPharma, Inc. PDLI Stock Holding History

Berkeley Capital Partners’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-19,471
Closed -$69K – 133
2015
Q4 		$69K Buy
+19,471
New +$81.5K 0.06% 111

Other funds holding PDLI

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GAM
Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Berkeley Capital Partners's PDLI Position: Q1 2016 in Review

Berkeley Capital Partners sold out of PDL BioPharma, Inc. (PDLI) in Q1 2016, closing a stake of 19,471 shares — an estimated $69K sold.

Berkeley Capital Partners first reported a position in PDLI in Q4 2015 and held it in 1 quarter. The position peaked at $69K in Q4 2015. 195 funds tracked by Wall St. Rank hold PDLI as of Q1 2016.

  • Berkeley Capital Partners reported no remaining PDL BioPharma, Inc. position as of Q1 2016 after selling out during the quarter.
  • Berkeley Capital Partners sold 19,471 PDL BioPharma, Inc. shares in Q1 2016, an estimated $69K.
  • Berkeley Capital Partners first reported a position in PDL BioPharma, Inc. in Q4 2015 and held it in 1 quarter.
  • Berkeley Capital Partners's PDL BioPharma, Inc. position peaked at $69K in Q4 2015.
  • 195 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2016.

Based on Berkeley Capital Partners's 13F filing for Q1 2016, filed 11 May 2016.